GlassScriptPhysician profile
Scott A Moulton
NPI 1811141211
$7,382.96
in general payments reported to CMS, 2019-2025
54 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $776 · 2021: $797 · 2022: $869 · 2023: $1,349 · 2024: $1,293 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,071.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,071.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,261.20 | 2019-2025 | Evenity, Repatha, Otezla |
| Novo Nordisk INC | $707.36 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $573.49 | 2019-2025 | |
| Lilly USA, LLC | $570.11 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $563.47 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $481.56 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $353.19 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $255.47 | 2020-2024 | Xarelto, Spravato |
| Novartis Pharmaceuticals Corporation | $214.06 | 2019-2025 | |
| Glaxosmithkline, LLC. | $194.49 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $187.22 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $159.91 | 2019-2022 | |
| Daiichi Sankyo INC. | $152.42 | 2022-2024 | Injectafer |
| Exact Sciences Corporation | $135.91 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $93.58 | 2023-2025 | Gemtesa |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Moulton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.